pH Partners Announces Strategic Partnership Between Entos and BioMarin

Nov 15, 2021 | Featured This Week

EDMONTON, AB, November 15, 2021, – pH Partners, LLC, (“PHP”) is excited to announce the partnership between Entos Pharmaceuticals and BioMarin Pharmaceutical Inc. to develop new treatments for a host of genetic diseases.

Erik Halvorsen, the lead Partner from pH on the deal said, “This partnership brings together one of the world’s leaders in rare diseases in BioMarin with one of the most innovative companies in the field of nucleic acid and gene editing delivery in Entos.  It is exciting to think about the millions of patients who will benefit from this collaboration.”

The Fusogenix platform developed by John Lewis utilizes a proteolipid nucleic acid delivery system with significant advantages over other LNP and AAV systems and is currently being used by Oisin Biotechnologies and OncoSenX to treat age related disorders and cancer respectively.

pH Partners is proud to work with industry leaders like John Lewis, Entos Pharmaceuticals and BioMarin Pharmaceutical Inc. to bring new treatments, and new hope, to patients around the world!

pH Partners, LLC, a boutique healthcare investment bank, served as the Exclusive Financial Advisor to Entos Pharmaceuticals.

About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare genetic diseases. The company’s portfolio consists of seven commercialized products and multiple clinical and preclinical product candidates. For additional information, please visit www.biomarin.com. Information on such website is not incorporated by reference into this press release.
BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.

About Entos Pharmaceuticals, Inc.
Entos develops next generation nucleic acid-based therapies using its proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix is formulated with FAST proteins to deliver mRNA or DNA directly into the cytosol of target cells for translation into protective and therapeutic vaccines and medicines. For more information, visit http://www.entospharma.com.

About pH Partners
pH Partners, LLC, is a boutique investment banking firm delivering capital formation, strategic partnership, and merger and acquisition services to companies at the convergence of Healthcare, Technology and the Consumer. The pH Partners team consists of senior-level executives with extensive backgrounds in investment banking, life sciences, medicine and operations, and have collectively closed over $20B in strategic advisory transactions, and have raised more $5B in capital for their clients. pH Partners is headquartered in Austin, Texas with offices in Houston, Portland and New York. To learn more, visit phpartners.com.

To read more, visit the press release here.

pH Partners’ transaction leads:
Benjamin Perkins
Managing Partner

Erik Halvorsen, Ph.D.
Partner